COMPANY PROFILE / #1715
Envisagenics
Long Island City, NYVenture Capital-Backed
OVERVIEW
Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine learning algorithms to analyze, predict, and interpret transcriptomic data, enabling researchers to identify and validate potential drug targets.
已融资40.45
最新估值150.00
员工数35
成立年份2014
公司概况
- Companies
- Envisagenics
- Description
- Developer of a bioinformatics platform designed to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine learning algorithms to analyze, predict, and interpret transcriptomic data, enabling researchers to identify and validate potential drug targets.
- Website
- www.envisagenics.com
- HQ Location
- Long Island City, NY
- Year Founded
- 2014
- Keywords
- cancer target, gene therapy, machine learning, predictive modeling, rna sequencing, rna splicing
- Competitors
- Deep Genomics, Partek, Standard BioTools, Miroculus, Caris Life Sciences, Wafergen Bio-Systems, Strand (Biotechnology), RainDance Technologies, Synpromics, Genotypic Technology, Oxford Gene Technology, Avitide, Cancer Genetics India, Ionpath, Oxford Nanopore Technologies, Diagenode, Cyclica, NanoString Technologies, GenapSys, Akoya Biosciences, Scienion, Qiagen
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 40.45
- First Financing Date
- 27-Jul-2015
- First Financing Size
- 0.10
- First Financing Valuation
- —
- Last Financing Date
- 01-Apr-2026
- Last Financing Deal Type
- Secondary Transaction - Private
- Last Financing Size
- —
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 150.00
- Last Known Valuation Date
- 18-Jul-2024
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 182.63
- Valuation Estimate Growth Rate
- 21.75%
- Active Investors
- Bristol-Myers Squibb, Dolby Family Ventures, Dynamk Capital, Empire State Development, Gillian Sandler, Hawktail, Johnson & Johnson Innovation - JLABS, M12, Madrona Venture Group, Myeloma Investment Fund, National Cancer Institute, National Institutes of Health, New York Ventures, Red Cell Partners, Third Kind Venture Capital, Topspin Consumer Partners, Upsher Management Company
- # Active Investors
- 17
- Acquirers
- —
团队与联系人
- Employees
- 35
- Employee Growth %
- -14.63% E
- Employee History
- 2026: 35, 2025: 41 E, 2024: 47, 2023: 39, 2022: 34, 2021: 21, 2020: 17, 2019: 13 E, 2018: 10 E, 2017: 6 E, 2016: 2
- Primary Contact
- Maria Pineda
- Primary Contact Title
- Co-Founder, Co-Chief Executive Officer & Board Member
- Primary Contact Email
- maria@envisagenics.com
- Primary Contact Phone
- +1 (516) 847-5485
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- -0.03%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 13
- Size Multiple
- 4.54x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 79
- Majestic Referring Domains
- 242
- SimilarWeb Unique Visitors
- 27
- SimilarWeb Unique Visitors Change
- -70
- SimilarWeb Growth Rate
- 0.00%
- SimilarWeb Growth Rate Percentile
- 9
- Success Probability Over Time – 1 Year
- 10%
- Success Probability Over Time – 3 Year
- 24%
- Success Probability Over Time – 5 Year
- 39%
记录来源：public.companies · 原始序号 #1715 · 所有字段均按数据库原值展示。